Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma
Authors:
- 10 December 2020
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 106 (3) , 398-407
Abstract
Objective and Method: Adult T‐cell leukemia/lymphoma (ATL) is an aggressive peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical records of 312 patients with aggressive ATL and analyzed the effect of chemotherapy dose intensity on prognosis in clinical practice.Result: As first‐line therapy, 62 patients underwent best supportive care (BSC) or single‐agent chemotherapy, and 235 underwent intensive chemotherapy. The median survival time (MST) was 0.58 years in the 312 total patients, and 0.13 years and 0.75 years in the BSC/single‐agent chemotherapy group and intensive chemotherapy group, respectively. The median average relative dose intensity (ARDI) of patients who received intensive chemotherapy was 60%. We divided patients into 3 groups according to ARDI. Those in the top tertile of ARDI (ARDI ≥ 75%, n = 82) had better overall survival compared with those in the intermediate tertile (45% ≤ ARDI < 75%, n = 79) (P < .0001), with MSTs of 4.69 and 0.75 years, respectively. The occurrence of organ dysfunction and infectious complications was comparable between the two ARDI groups.Conclusion: Higher ARDI improves prognosis in patients with aggressive ATL in clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantationHaematologica, 2017
- Characterization of patients with aggressive adult T-cell leukemia–lymphoma in Okinawa, Japan: a retrospective analysis of a large cohortInternational Journal of Hematology, 2016
- Treatment and survival among 1594 patients with ATLBlood, 2015
- Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)British Journal of Haematology, 2014
- Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/LymphomaJournal of Clinical Oncology, 2012
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801Journal of Clinical Oncology, 2007
- Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 1991
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.Journal of Clinical Oncology, 1990
- Adult T-cell leukemia: clinical and hematologic features of 16 casesBlood, 1977